0001854270-24-000013.txt : 20240202
0001854270-24-000013.hdr.sgml : 20240202
20240202172438
ACCESSION NUMBER: 0001854270-24-000013
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240201
FILED AS OF DATE: 20240202
DATE AS OF CHANGE: 20240202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KNOBELMAN DEBORAH
CENTRAL INDEX KEY: 0001931509
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40440
FILM NUMBER: 24592881
MAIL ADDRESS:
STREET 1: C/O SENTI BIOSCIENCES, INC.
STREET 2: 2 CORPORATE DRIVE FIRST FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Senti Biosciences, Inc.
CENTRAL INDEX KEY: 0001854270
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 862437900
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 CORPORATE DRIVE, FIRST FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 382-3281
MAIL ADDRESS:
STREET 1: 2 CORPORATE DRIVE, FIRST FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Senti Biosciences, Inc.\
DATE OF NAME CHANGE: 20220615
FORMER COMPANY:
FORMER CONFORMED NAME: Dynamics Special Purpose Corp.
DATE OF NAME CHANGE: 20210331
4
1
wk-form4_1706912660.xml
FORM 4
X0508
4
2024-02-01
0
0001854270
Senti Biosciences, Inc.
SNTI
0001931509
KNOBELMAN DEBORAH
C/O SENTI BIOSCIENCES, INC.
2 CORPORATE DRIVE FIRST FLOOR
SOUTH SAN FRANCISCO
CA
94080
0
1
0
1
Chief Financial Officer
Head of Corporate Development
0
Common Stock
2024-02-01
4
A
0
101000
0
A
131000
D
Stock Option (Right to Buy)
0.46
2024-02-01
4
A
0
152000
0
A
2034-01-31
Common Stock
152000
152000
D
The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award vest in three substantially equal annual installments over three years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.
The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.
/s/ Mike Rhee, attorney-in-fact
2024-02-02